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Two Cases of Infantile Botulism in Virginia that Highlight the Importance of Early Clinical
Diagnosis and Proper Reporting, Treatment, and Prevention.
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Purpose:
Infantile botulism is a rare condition that primarily affects infants under the age of 6
months. This disease is caused by ingestion of Clostridium Botulinum spores that are found in
soil or honey. Once ingested, the spores germinate into bacteria that colonize the infant’s
immature intestinal tract and synthesize a toxin. This toxin irreversibly binds acetylcholine
receptors, leading to the clinical presentation of progressively worsening constipation, weakness,
hypotonia, poor feeding, weak cry, and decreased activity. If enough toxins are released, lifethreatening flaccid paralysis with respiratory failure can ensue. Fortunately, with high clinical
suspicion, a physician can gain access to life-saving Botulism Immune Globulin Intravenously
(BIG-IV) prior to laboratory confirmation. Early administration of Botulism Immune Globulin
Intravenous (BIG-IV) can significantly improve outcomes by neutralizing any systemically
circulating botulinum toxin. With early diagnosis and treatment, full recovery without neurologic
sequelae is likely. Here we present two infants from Southwest Virginia who were admitted to a
children’s hospital. These cases illustrate the typical presentation of infantile botulism, an
approach to management, the possible clinical course, and opportunities for prevention.

Case Summaries
Case 1
A previously healthy 5-week-old Caucasian male was taken to his primary care provider (PCP)
for poor feeding and decreased activity. His mother reported that he was in his normal state of
health until 2 days prior when he was noted to be increasingly somnolent. He was too weak to
suck and had started to refuse the bottle. She also described a weak cry. These symptoms
continued to progress until she noticed increased work of breathing. Review of systems was
positive for decreased urination and stooling with his last bowel movement being two days
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ago. She denied any fever, congestion, cough, vomiting or seizures. He was breast fed with
formula supplementation and had not been introduced to any other foods or had any other
ingestions. She denied sick contacts. His past medical history was notable for a 2-week NICU
stay for jaundice, hypoglycemia and respiratory distress after being delivered via C-section at 37
weeks. He received his Hepatitis B vaccination prior to discharge without complication.
On physical exam at his PCP’s office, his vitals were normal. He was noted to be somnolent and
mottled with poor tone, a weak gag, and minimal suck. These findings prompted immediate
transport to a tertiary medical center.

In the Emergency Department (ED), he was still afebrile with normal vital signs. His physical
exam revealed hypotonia with poor head control. He had a weak cry and inadequate swallow. A
broad work-up was pursued in line with the differential diagnosis. A septic work-up, including
lumbar puncture returned reassuring results. The patient had no electrolyte abnormality, a
negative urine drug screen, a normal brain CT, and an unremarkable X-ray of the chest and
abdomen. He received intravenous fluids and antibiotics and was transferred to the pediatric
intensive care unit (PICU) for further evaluation and treatment.

In the PICU, results continued to come back normal, including ammonia, thyroid stimulating
hormone (TSH), lactate, and homocysteine. His newborn screen was tracked down and was
normal. The Infant Botulism Treatment and Prevention Program in California (IBT&PC)
(2020a) was called shortly after admission and recommended further work-up and a neurology
consult, feeling that a longer history of constipation would be likely if this was botulism. His
EEG was normal, EMG was unavailable for infants his age at this institution and the neurologist
suspected botulism. The approval process for treatment with BIG-IV was started after
consultation with the Virginia Department of Health, Centers for Disease Control (CDC), and
stakeholders at the IBT&PC. A sterile enema was used to obtain a stool sample for botulinum
toxin testing following a strict protocol on sample collection. On day 2 of hospitalization, the
patient’s respiratory distress worsened, and he was placed on BIPAP which progressed to
intubation by day 3. Meanwhile, approval was granted for treatment with BIG-IV and it was
sent to the patient’s medical center and administered that evening.
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The patient tolerated BIG-IV administration without complication. On day 4 of admission, he
had zero respiratory drive, no motor response to stimulation, minimal eye-opening and no cough
or gag reflex. On day 5, he showed mild improvement in symptoms, but developed a fever and
was treated for ventilator-associated pneumonia. Three days post-BIG IV treatment, the patient
regained his gag, suck, and cough reflexes and had improved tone, moving all of his extremities.
He also began having multiple bowel movements a day with the help of polyethylene glycol and
glycerin suppositories. The patient was extubated on hospital day 7, returned a positive
Clostridium botulinum test on day 10, and discharged home on hospital day 21 with nasogastric
gavage feedings. Neurologically, he has made a full recovery.
During his hospital stay, additional history uncovered that the mother’s fiancé worked for a
concrete company and regularly came home covered in concrete, mud, and dirt. He rarely
changed clothes or removed his shoes prior to entering the home. We believed this to be the
source of our patient’s exposure.

Case 2
A previously healthy 4-week-old Latino male was taken to his PCP multiple times over a week
for constipation. Several home interventions such as rectal stimulation and Karo syrup added to
his formula were unsuccessful. During the second week of his constipation, he started to have
signs of poor feeding and was taken to the emergency department (ED) where the mother
reported decreased oral intake and urine output. She also reported a weak cry and less activity.
In the ED, he received an abdominal x-ray that was normal and IV fluids for dehydration. The
family was discharged home with return precautions. He returned to the ED less than 4 hours
after discharge with continued concerns. He had had one small dark bowel movement after a
suppository. He was not taking any formula and his activity levels had continued to decline. He
was no longer interacting with his caregivers, and they noticed that he was weaker. Review of
systems was otherwise negative for cough, congestion, vomiting or fever. Past medical history
revealed a previously healthy male born at 37.6 weeks via caesarean section without
complications. He had received Hepatitis B immunization without adverse reaction and had a
normal newborn screen. The mother denied any sick contacts or ingestions other than formula.
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He lived with his mom, dad, and older siblings and also spent time at his grandparents’ house
where there was ongoing construction inside and outside the home.

On physical exam, the ED physician noted a sunken fontanelle, dry mucous membranes, a weak
cry, sluggish capillary refill, decreased eye tracking, and global hypotonia. He was found to be
hypothermic and tachycardic on vital signs but was not in respiratory distress. Given his
presentation, he was given IV fluids and empiric antibiotics following blood, urine and spinal
fluid cultures. Because of his lethargy, the PICU was consulted for admission. He did not have
increased white blood cells in his blood, urine or spinal fluid. He also did not have an electrolyte
abnormality or elevated lactate or ammonia to suggest an inborn error of metabolism. There was
no history of trauma and a head CT was unremarkable. He had a nasogastric (NG) tube placed
to provide enteral nutrition and was admitted to the PICU.

Prior to admission to the PICU, the clinical suspicion for botulism was high. The Infant
Botulism Prevention and Treatment Center (2020a) was contacted. They agreed this patient had
a high suspicion for infantile botulism and sent BIG-IV the next morning. He had no clinical
signs of improvement until day 4 of hospitalization when he showed improved strength and
mental status. By day 5, he was tolerating all his feeds orally and his nasogastric tube was
removed. On day 7, he was discharged home with near baseline status and no further
interventions at home. Five days after being discharged home, his stool became positive for
Clostridium botulinum toxin B.

Discussion:
Infantile botulism is caused by neurotoxins released into an infant’s circulation following the
ingestion of Clostridium botulinum spores. The Clostridium bacteria is an obligate anaerobe that
is a spore-forming gram-positive bacillus. It produces a heat-labile neurotoxin that is the most
potent toxin known on planet earth. Clostridium can produce 7 different toxins, identified as AG with some debate about an 8th (H). The vast majority of infantile botulism cases are from
neurotoxin A and B. Infantile botulism is more common than both food and wound botulism
combined (Cox & Hinkle, 2002; American Academy of Pediatrics, 2018).
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The botulinum toxin disrupts the release of acetylcholine from the presynaptic neurons and
prevents muscle excitation and contraction (American Academy of Pediatrics, 2018). When
70% of terminals are impaired, the disease begins to manifest itself. Common symptoms are
constipation, weakness, hypotonia, cranial nerve impairment, including ptosis, sluggish pupillary
reflex, weak gag, cry, suck and difficulty swallowing. These can be vague complaints and ones
often heard in the pediatric office. It is not until 90% of the neuromuscular terminals are
impaired that you will start to have respiratory failure and flaccid paralysis. Around half of all
infants with infantile botulism will require mechanical ventilation (Clemmens & Bell,
2007). The presentation is predictable once a certain level of toxemia is reached. It is always a
descending, bilateral, symmetric, flaccid paralysis.

Due to the vague nature of these presenting symptoms and the low incidence, infantile botulism
is often misdiagnosed in the early stages of the disease (Francisco & Arnon, 2007) Patients are
often seen multiple times and undergo extensive workups as lethargy progresses (Infant Botulism
Treatment & Prevention Program, 2020a). Clostridium botulinum infection should be on the
differential diagnosis of an infant presenting with subacute progression of motor weakness,
lethargy, poor feeding, and constipation. Workup should evaluate for infection, inborn errors of
metabolism, non-accidental trauma, spinal muscular atrophy, electrolyte derangements,
hypothyroidism, and other toxic ingestions. By excluding these other possibilities and narrowing
your differential, you will be able to solidify your suspicion of infantile botulism and proceed
with appropriate management.

Summary Recommendation:
Management and Treatment:
Botulism is at first a clinical diagnosis. Management of infant botulism consists of both
supportive care and the administration of the botulism antitoxin, Botulism Immune Globulin
Intravenous (BIG-IV). You should not wait for laboratory confirmation to begin treatment. BIGIV neutralizes all circulating toxins, stopping the progression of the disease while the body
regenerates motor neurons (Infant Botulism Treatment & Prevention Program, 2020b;
Thompson, Filloux, & Van Orman, 2005). To obtain the antitoxin expeditiously, you should
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contact both your state health department and the Infantile Botulism Treatment and Prevention
Center in California (Figure 1) (Infant Botulism Treatment & Prevention Program, 2020b;
Centers for Disease Control, 2020). The state health department will assist in obtaining the stool
specimen using a strict collection protocol (Virginia Department of Health, 2019). They will
also help coordinate with the IBT&PC, which is the gatekeeper for the national supply of the
antitoxin.
The infant should fully recover from the illness with appropriate supportive care with or without
treatment with BIG-IV. In a 5-year randomized, double-blinded, placebo-controlled trial,
however, there was a substantial decrease in all measures of disease-associated morbidity with
the use of immune globulin in the first few days of admission. The length of intensive care stay,
mechanical ventilation, and tube feedings were decreased and the most significant of these
reductions was the length of the average hospital stay from 5.7 weeks to 2.6 weeks in the
treatment group (P<0.001) (Arnon, 2007; Long, 2007; Arnon et al., 2006). To date, there have
not been any reported studies showing significant adverse effects associated with BIG-IV. This
risk to benefit ratio strongly supports early administration of the drug (Arnon et al., 2006).

Most cases are treated in the intensive care unit as around 50% of cases will need respiratory
support. Since it also affects the cranial nerves, successful swallowing can become
compromised and affected patients are at risk of aspiration and metabolic derangements (Cox &
Hinkle, 2002; Clemmens & Bell, 2007; Long, 2007). Supportive care should be given via
intravenous fluids and nasogastric tube feedings when appropriate. The prognosis is excellent
with appropriate supportive care (Arnon et al., 2006). Recovery is progressive as it takes time to
replenish the motor endplates (Infant Botulism Treatment & Prevention Program, 2020a).
Diaphragmatic function tends to recover before peripheral muscles allowing the patient to come
off respiratory support and transfer out of the ICU as they make their full recovery (Cox &
Hinkle, 2002).
Public Health Message and Prevention:
Most cases of infant botulism have no definitive source of exposure and can be very difficult to
fully prevent because the bacteria is found naturally in the soil and dust. There are, however,
measures that can be done to reduce the likelihood of exposure. The most common preventive
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measure is not to expose an infant to honey or honey products prior to the age of one. This is an
absolute recommendation. Honey can contain the bacteria even after processing. Honey is safe
only for people over the age of one as the botulism spores are no longer dangerous to a healthy
and mature digestive tract. A detailed history should include asking about honey
consumption. Per the Redbook on Pediatric Infectious Diseases, the incubation period can be
between 3-30 days (American Academy of Pediatrics, 2018).

Unfortunately, more than 85% of infants have no honey exposure and other causes should be
investigated. Since Clostridium spores are naturally occurring in the soil, it is important to ask
about the occupation of all caregivers and any recent construction in or near the
home. Occupations such as construction workers, excavators, farmers, and those employed in
concrete and masonry are at high-risk of bringing spores into the home. Both of our cases had
no exposure to honey but had a parent or caregiver in a high-risk occupation.

Most cases of infantile botulism worldwide are diagnosed in the United States with greater than
50% of cases being in California (Centers for Disease Control & Prevention, 2016). Clostridium
botulinum spores have been found in the soil in all 50 states. Cases in Virginia have been
primarily caused by toxin B with some reports of toxin A (Centers for Disease Control &
Prevention, 2016). The cases in Virginia historically have all been responsive to the BIG-IV.

It is important for health care providers to ask about caregiver occupations and childcare
arrangements at each visit. If a parent or caretaker is employed in a high-risk occupation, health
care providers should take time to educate families on the risk factors for exposure to
infants. They should be advised to remove work boots outside and remove all work clothes prior
to contact with the infant. A clean breast milk or formula prep area is important and those
preparing the bottle should be aware of possible exposures. If there is any construction near or in
the home, homeowners should make sure all windows are shut and the area where the infant’s
food is prepared should be protected from any dust or dirt contamination (Figure 2).

While still rare, infantile botulism exists in Virginia. It is the responsibility of the medical and
public health teams to identify high-risk families, educate them on prevention strategies, identify
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botulism cases and initiate timely, appropriate treatment. A good social and occupational history
is important as honey consumption is not the most common way to contract the disease. Nailing
the diagnosis of infantile botulism and initiating timely treatment will expedite a full, sweet
recovery.

Figure 1:
Reporting Suspected Infantile Botulism and Obtaining BIG-IV in Virginia:
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Figure 2:
Caregiver Handout on Preventing Infantile Botulism:
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*For more information about infant botulism, BabyBIG® (BIG-IV) and the Infant Botulism and
Treatment Program, please visit the websites listed below:
https://www.cdph.ca.gov/Programs/CID/DCDC/Pages/InfantBotulism.aspx
http://www.infantbotulism.org/

